Posaconazol Viatris 40 mg/ml Sospensione orale Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

posaconazol viatris 40 mg/ml sospensione orale

viatris pharma gmbh - posaconazolum - sospensione orale - posaconazolum 200 mg, acidum citricum monohydricum, natrii dihydrogenocitras anhydricus, natrii benzoas 10 mg, natrii laurilsulfas, simeticonum, methylcellulosum, acidum sorbicum, xanthani gummi, glycerolum, glucosum liquidum 2108.5 mg, e 171, aromatica (kirschen), aqua purificata ad suspensionem pro 5 ml corresp. natrium 5.91 mg. - infezioni fungine - synthetika

Posaconazol Viatris 100 mg Compressa gastroresistente Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

posaconazol viatris 100 mg compressa gastroresistente

viatris pharma gmbh - posaconazolum - compressa gastroresistente - posaconazolum 100 mg, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, triethylis citras, xylitolum, hydroxypropylcellulosum, e 310, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum, natrii stearylis fumaras, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 172 (flavum), pro compresso obducto corresp. natrium 2.4 mg. - infezioni fungine - synthetika

Etoricoxib Viatris 30 mg Compresse rivestite con film Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

etoricoxib viatris 30 mg compresse rivestite con film

viatris pharma gmbh - etoricoxibum - compresse rivestite con film - etoricoxibum 30 mg, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, hypromellosum, lactosum monohydricum 0.84 mg, e 171, triacetinum, cera carnauba, e 133, e 172 (nigrum), e 172 (flavum), pro compresso obducto corresp. natrium 0.45 mg. - inibitore selettivo cox-2 inibitori - synthetika

Etoricoxib Viatris 60 mg Compresse rivestite con film Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

etoricoxib viatris 60 mg compresse rivestite con film

viatris pharma gmbh - etoricoxibum - compresse rivestite con film - etoricoxibum 60 mg, calcii hydrogenophosphas, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, hypromellosum, lactosum monohydricum 1.68 mg, e 171, triacetinum, cera carnauba, e 172 (flavum), e 132, pro compresso obducto corresp. natrium 0.9 mg. - inibitore selettivo cox-2 inibitori - synthetika

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Europos Sąjunga - italų - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agenti antitrombotici - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segment elevation infarto miocardico acuto, in combinazione con asa in medicalmente trattati i pazienti eleggibili per la terapia trombolitica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. per ulteriori informazioni, si prega di fare riferimento alla sezione 5.

Olmesartan HCT Viatris 20/12.5 mg Fimtabletten Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

olmesartan hct viatris 20/12.5 mg fimtabletten

viatris pharma gmbh - olmesartanum medoxomilum, hydrochlorothiazidum - fimtabletten - olmesartanum medoxomilum 20 mg, hydrochlorothiazidum 12.5 mg, carmellosum natricum conexum, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, silica colloidalis anhydrica, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 6000, talcum, e 171, pro compresso obducto, natrium 1.4837 mg. - essenziale ipertonia - synthetika

Olmesartan HCT Viatris 20/25 mg Fimtabletten Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

olmesartan hct viatris 20/25 mg fimtabletten

viatris pharma gmbh - olmesartanum medoxomilum, hydrochlorothiazidum - fimtabletten - olmesartanum medoxomilum 20 mg, hydrochlorothiazidum 25 mg, carmellosum natricum conexum, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, silica colloidalis anhydrica, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 6000, talcum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto, natrium 2.9674 mg. - essenziale ipertonia - synthetika

Olmesartan HCT Viatris 40/12.5 mg Fimtabletten Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

olmesartan hct viatris 40/12.5 mg fimtabletten

viatris pharma gmbh - olmesartanum medoxomilum, hydrochlorothiazidum - fimtabletten - olmesartanum medoxomilum 40 mg, hydrochlorothiazidum 12.5 mg, carmellosum natricum conexum, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, silica colloidalis anhydrica, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 6000, talcum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto, natrium 2.9674 mg. - essenziale ipertonia - synthetika

Olmesartan HCT Viatris 40/25 mg Fimtabletten Šveicarija - italų - Swissmedic (Swiss Agency for Therapeutic Products)

olmesartan hct viatris 40/25 mg fimtabletten

viatris pharma gmbh - olmesartanum medoxomilum, hydrochlorothiazidum - fimtabletten - olmesartanum medoxomilum 40 mg, hydrochlorothiazidum 25 mg, carmellosum natricum conexum, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, silica colloidalis anhydrica, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 6000, talcum, e 171, pro compresso obducto, natrium 2.9674 mg. - essenziale ipertonia - synthetika

Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Europos Sąjunga - italų - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - aripiprazolo - schizophrenia; bipolar disorder - psicolettici - aripiprazolo mylan pharma è indicato per il trattamento della schizofrenia negli adulti e negli adolescenti di età pari o superiore a 15 anni. aripiprazole mylan pharma è indicato per il trattamento di moderata a grave episodi maniacali nel disturbo bipolare e per la prevenzione di un nuovo episodio maniacale in adulti che hanno sperimentato episodi maniacali prevalentemente e i cui episodi maniacali risposto alla aripiprazole trattamento. aripiprazole mylan pharma è indicato per il trattamento fino a 12 settimane di moderate a gravi episodi maniacali nel disturbo bipolare negli adolescenti di età compresa tra 13 anni e più vecchi.